NEW YORK, April 1 (Reuters) - Biogen Idec Inc. (BIIB.O: Quote, Profile, Research) , which recently suspended sales of its new multiple sclerosis drug Tysabri, on Friday withdrew the financial forecast it issued in February. Biogen had forecast 2005 earnings, excluding one-time items, of between $1.60 a share and the low $1.70s. Analysts were forecasting $1.60, on average, according to Reuters Estimates.
